Share on StockTwits

Cytokinetics (NASDAQ:CYTK)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity in a research note issued on Monday, Analyst Ratings Net reports. They currently have a $9.00 price target on the stock, down from their previous price target of $22.00. Canaccord Genuity’s price objective would suggest a potential upside of 101.79% from the stock’s previous close.

Shares of Cytokinetics (NASDAQ:CYTK) traded down 2.83% on Monday, hitting $4.46. The stock had a trading volume of 5,102,042 shares. Cytokinetics has a 52-week low of $4.30 and a 52-week high of $14.28. The stock has a 50-day moving average of $9.50 and a 200-day moving average of $8.0. The company’s market cap is $160.9 million.

Cytokinetics (NASDAQ:CYTK) last released its earnings data on Thursday, February 6th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.29. The company had revenue of $24.30 million for the quarter, compared to the consensus estimate of $19.14 million. Analysts expect that Cytokinetics will post $-1.09 EPS for the current fiscal year.

CYTK has been the subject of a number of other recent research reports. Analysts at Needham & Company LLC cut their price target on shares of Cytokinetics from $25.00 to $15.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at MLV & Co
downgraded shares of Cytokinetics from a “buy” rating to a “hold” rating in a research note on Friday. They now have a $5.00 price target on the stock, down previously from $26.00. Finally, analysts at Piper Jaffray downgraded shares of Cytokinetics from an “overweight” rating to a “neutral” rating in a research note on Friday. They now have a $7.00 price target on the stock, down previously from $18.00. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $12.20.

Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.